Table 1 Baseline characteristics of chronic hepatitis C patients with thrombocytopenia with or without significant platelet count improvement
Variable | All patients (n = 104) | With significant platelet count improvement (n = 44) (42.3%) | Without significant platelet count improvement (n = 60) (57.7%) | P-value |
|---|---|---|---|---|
Age (years)a | 66.1 (37–88) | 64.4 (46–84) | 67.8 (37–88) | 0.33 |
Male (%) | 40 (38.5%) | 12 (27.3%) | 28 (46.7%) | 0.066 |
Alcoholism (%) | 5 (4.8%) | 2 (4.5%) | 3 (5%) | 1.00 |
Fatty liver | 29 (27.9%) | 14 (31.8%) | 15 (25.5%) | 0.510 |
ALT(U/L)a | 75 (20–492) | 71.5 (20–448) | 75.0 (20–492) | 0.603 |
AST(U/L)a | 54 (10–431) | 43.5 (10–410) | 58.5 (23–431) | 0.194 |
Albumin (g/dL)a | 4.1 (3–5) | 4.0 (3–5) | 4.1 (3–5) | 0.532 |
Total bilirubin (mg/dL)a | 0.80 (0–3) | 0.9 (0–2) | 0.8 (0–3) | 0.971 |
e-GFR (ml/min/1.73 m2)a | 75.7 (4.5–132.1) | 75.5 (4.5–118.0) | 76.0 (11.9–132.1) | 0.594 |
Platelet (× 103/µL)a | 110.5 (32–149) | 115.5 (32–149) | 106.5 (41–148) | 0.932 |
Prothrombin time (INR)a | 1.1 (0.9–1.3) | 1.1 (1.0–1.3) | 1.1 (0.9–1.3) | 0.203 |
AFP (ng/mL)a | 6.0 (2–253) | 7.2 (2–253) | 5.1 (2–219) | 0.064 |
Baseline HCV viral load (IU/mL)a | 1.35 × 106 (176–35.8 × 106) | 1.63 × 106 (1890–32.8 × 106) | 1.13 × 106 (176–35.8 × 106) | 0.453 |
HCV genotype 1 (%) | 71 (68.3%) | 32 (72.7%) | 39 (65.0%) | 0.523 |
Interferon experienced (%) | 31 (29.8%) | 16 (36.4%) | 15 (25.0%) | 0.278 |
HBV co-infection (%) | 5 (4.8%) | 2 (4.5%) | 3 (5%) | 1.00 |
FIB-4a | 4.2 (1.05–20.17) | 3.6 (1.05–19.92) | 4.9 (1.32–20.17) | 0.175 |
Advanced fibrosis (%) | 72 (69.2%) | 26 (59.1%) | 46 (76.7%) | 0.085 |
HCC history (%) | 28 (26.9%) | 10 (22.7%) | 18 (30.0%) | 0.504 |
Splenomegaly (%) | 38 (36.5%) | 12 (27.3%) | 26 (43.3%) | 0.104 |
Ascites (%) | 9 (8.4%) | 1 (2.3%) | 8 (12.7%) | 0.075 |
TPO (pg/mL)a | 132.3 (32.0–3944.0) | 172.2 (70.0–3944.0) | 74.8 (32.0–3850.0) | < 0.001 |